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Abstract 
Background: Bone morphogenetic protein-2 (BMP-2) is a pleiotropic, secreted molecule with diverse effects. The 
potent ability of BMP-2 to stimulate bone growth prompted its widespread clinical use for arthrodesis (spine fusion). 
However, elevated post-operative pain in patients treated with BMP-2 has been increasingly reported. Determining 
whether BMP-2 induces pain directly or whether it induces neuroinflammation, which could lower the threshold 
for pain, is important for developing therapeutic interventions. We therefore modeled the clinical use of BMP-2 for 
posterior lumbar fusion by implanting absorbable collagen sponges soaked with either recombinant human BMP-2 
(rhBMP-2) or vehicle above the L4–L5 transverse processes of rat spine.
Results: Using microarray analysis we found that implantation of rhBMP-2-soaked absorbable collagen sponges 
resulted in altered expression of numerous pro-inflammatory genes in the adjacent dorsal root ganglia (DRG) show-
ing that implantation of rhBMP-2/absorbable collagen sponges triggers potent neuroinflammatory responses in the 
DRG-2. Interestingly, direct BMP-2 treatment of DRG explants resulted in changes in gene expression that were not 
specifically pro-inflammatory. Rats implanted with rhBMP-2 in absorbable collagen sponges also exhibited a transient 
change in thermal and mechanical sensitivity indicating that rhBMP-2 applied to the lumbar spine could increase 
pain sensitivity. Immunohistochemical analysis indicated macrophage infiltration in the DRG and spinal nerve in rats 
implanted with rhBMP-2/absorbable collagen sponges or absorbable collagen sponges alone, but not in rats that 
underwent surgery without implantation of the absorbable collagen sponges suggesting that the sponges con-
tributed to the biological response. Indeed, analysis of DRGs taken from rats implanted with absorbable collagen 
sponges without rhBMP-2 showed a significant change in gene expression distinct from DRGs from rats undergoing 
surgery only.
Conclusions: Our data indicate that implantation of rhBMP-2/absorbable collagen sponges on the lumbar spine 
triggers potent neuroinflammatory responses in the DRG. Importantly, however, these BMP-2 effects may be partially 
mediated through a response to the absorbable collagen sponges.
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Background
Bone morphogenetic proteins (BMPs) have multiple func-
tions in growth and differentiation, including promo-
tion of the development of cartilage and bone [1]. The 
osteoinductive properties of BMP-2 prompted its devel-
opment into clinical use to promote bone growth and 
fracture healing, including arthrodesis (spine fusion). Each 
year, nearly 500,000 people undergo arthrodesis proce-
dures for treating conditions of the spine. Until the devel-
opment of BMP-2, arthrodesis was mainly performed 
using bone graft, typically harvested from the iliac crest 
of the same patient. FDA approval of recombinant human 
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BMP-2 (rhBMP-2) for interbody fusion in the anterior 
lumbar spine was initially widely welcomed by orthope-
dic surgeons as it enabled more rapid spinal fusion with-
out the morbidity associated with a second harvesting 
surgical site [2, 3]. Subsequently, many surgeons started 
performing “off-label” procedures with rhBMP-2 in all 
spinal regions [4]. However, increasing evidence indicates 
that rhBMP-2 administration is not more efficacious than 
bone graft [5]. Further, there are now numerous reports 
of side effects including ectopic bone formation, male 
infertility and additional neurological problems [6–9]. 
In 2008 the FDA issued a warning about life threatening 
complications associated with off-label use of rhBMP-2 in 
the anterior cervical spine [10]. However, rhBMP-2 is still 
widely used in the lumbar spine. A recent comprehensive 
meta-analysis of several clinical trials also revealed a sig-
nificantly increased risk ratio for the development of post-
operative back and leg pain in patients when rhBMP-2 is 
used for posterolateral arthrodesis, a surgical procedure 
used to fuse two or more vertebrae [5].
BMP-2 receptors, which propagate BMP-2 signaling in 
part by phosphorylating the BMP-2 specific transcrip-
tional factors Smad1/5/8 [11], are expressed in nocicep-
tive neurons of the dorsal root ganglia (DRG) and in pain 
processing lamina of the dorsal horn of the spinal cord 
[12]. While it is not known whether BMP-2 participates 
in nociceptive processing, the related molecules, trans-
forming growth factor-β (TGF-β) and activin A, have 
prominent roles in nociception, with exogenous admin-
istration of these molecules exerting anti- or pro-nocice-
ptive effects in a manner dependent on route of injection 
[12–15]. Thus, as rhBMP-2 is placed in close proximity 
to the DRG and spinal nerve in posterolateral arthro-
desis, one possibility for the pain reported by rhBMP-2 
arthrodesis patients is direct activation of nociceptors by 
rhBMP-2. However, it is also possible that rhBMP-2 may 
induce pain indirectly, for example by triggering neuroin-
flammation [16–21], which could lead to sensitization of 
nociceptors. In this paper we have modeled the off-label 
use of rhBMP-2, implanted within an absorbable colla-
gen sponge (ACS) and characterized its effects on DRGs 
adjacent to its placement. We show that the effects of 
rhBMP-2 on nociception are mediated by neuroinflam-
matory changes, potentially enhanced by macrophage 
recruitment by the absorbable collagen sponge. These 
data suggest that some adverse effects of rhBMP-2 appli-




All animal and care procedures were approved by the 
Institutional Animal Care and Use Committee of the 
Uniformed Services University and performed in accord-
ance with the ARRIVE guidelines. Sasco Sprague-Dawley 
female rats (225–275  g), purchased from Charles River 
Laboratories (Frederick, MD, USA), were housed in 
regular cages (2 rats/cage) with access to food and water 
ad  libitum on a 12:12 reversed light/dark cycle in USU 
animal facilities. Rats were allowed to acclimatize to the 
animal facilities for a week after arrival.
Materials
Recombinant human bone morphogenetic protein-2 
(rhBMP-2), carrier free, was purchased from R&D Sys-
tems (Minneapolis, MN, USA). Absorbable bovine type 
I collagen sponges (ACS; Avitene Ultrafoam) were pur-
chased from Davol Inc (Warwick, RI, USA). rhBMP-2 
was resuspended at a concentration of 100  μg/ml in 
vehicle (333.02  mM glycine, 25.14  mM l-glutamic acid, 
1.71  mM NaCl, 0.5% (w/v) sucrose, and 0.01% (v/v) 
Tween 80, pH 4.5) on the day of surgery. Primers were 
synthesized by Integrated DNA Technologies (Coralville, 
IA, USA). Rat Ref-12 Expression BeadChips were pur-
chased from Illumina (San Diego, CA, USA).
Experimental design
Rats were randomly divided into three groups
Group 1:  Surgery plus implantation with rhBMP-2 in 
absorbable collagen sponges (rhBMP-2/ACS)
Group 2:  Surgery plus implantation with vehicle in 
absorbable collagen sponges (sponge or 
vehicle/ACS)
Group 3:  Surgery alone (no sponge)
The number of animals that underwent these implanta-
tion surgeries for each of the readouts discussed in this 
paper are shown in Table  1. RNA was extracted from 
DRGs taken from all of these rats. For microarray analysis 
only the best quality and highest concentration four RNA 
samples were sent off for analysis, as the requirements for 
the amount of RNA and its quality were very stringent 
for the analysis to proceed. Behavioral analyses were con-
ducted on a different cohort of rhBMP-2/ACS (n =  12) 
and vehicle/ACS (n = 11) animals. To examine changes 
in the DRG by immunohistochemistry, three groups of 
rats were sacrificed on days 7–8; rhBMP-2/ACS (n = 9), 
vehicle/ACS (n  =  6) animals and ‘no sponge’ animals 
(n = 5). No animal was excluded from the study except 
for technical problems with the material extracted from 
it.
Animal surgery
Ketamine/xylazine (80 and 10  mg/kg; respectively) was 
injected i.p. to induce general anesthesia. The backs of 
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rats were shaved and aseptically prepared. Rats were 
placed in sternal recumbency on a covered heating pad 
and a surgical microscope was used to make a dorsal mid-
line skin incision overlying the spinous processes from L3 
to S1. The dorsal fascia and adipose tissue was dissected 
between L3 to S1 and the underlying muscle was cut just 
adjacent to the spinous process down to and near the 
facet joint. L4 and L5 transverse processes were exposed 
by retracting the overlying muscle. No decortication was 
performed. Two absorbable collagen sponges (ACSs) 
each soaked with either 400 μl of rhBMP-2 (100 μg/ml) 
or vehicle (333.02  mM glycine, 25.14  mM l-glutamic 
acid, 1.71 mM NaCl, 0.5% (w/v) sucrose, and 0.01% (v/v) 
Tween 80, pH 4.5) were implanted unilaterally over the 
L4–5 transverse processes. Thus, each animal either 
received 80  µg rhBMP-2 (BMP/ACS) or only vehicle 
(Vehicle/ACS). Additionally, a set of ‘no sponge’ animals 
received the identical surgery but no ACS implants. The 
overlying fascia and then skin of animals were closed 
using a 6.0 nylon suture. Animals were returned to hous-
ing facility once they recovered from anesthetic and 
began walking (approximately 3 h after surgery) and each 
animal was monitored daily.
Behavioral testing
Behavioral testing was performed to evaluate the func-
tional changes in the animals undergoing posterolateral 
arthrodesis with or without the use of rhBMP-2. Post-
operative changes in nociception were evaluated using 
a Von Frey mechanical withdrawal test and a thermal 
sensitization assessment relative to baseline recordings 
obtained before surgery. Investigators were blinded to 
the group assignment of each rat, as one investigator per-
formed the surgeries, and a second performed the behav-
ioral measurements. All behavioral experiments were 
performed between the hours of 9 am and 12  pm, in a 
dark room.
Von Frey mechanical withdrawal test
Rats were placed unrestrained under plastic enclosures 
on an elevated wire mesh platform and allowed to accli-
mate for at least 30 min. Sugared cereal was given to rats 
during the acclimation period and occasionally during 
the stimulation period in order to prevent animals from 
falling asleep. Cereal was never given immediately before 
stimulation of a paw. The mechanical withdrawal thresh-
old test was performed by applying an ascending series 
of calibrated nylon monofilament von Frey hairs (Ugo 
Basile, Italy) perpendicular to the mid-plantar surface of 
each animal’s hind paw at a slow, constant speed until the 
hair bent. A sharp withdrawal during the application of 
the hairs or flinching immediately upon removal of the 
hairs was considered a positive response. Each hair was 
applied to the hind paw a maximum of five times (i.e., 5 
trials) unless threshold was reached. Occasionally it was 
observed that animals responded strongly to one hair 
(e.g., 80 or 100% withdrawal) and very weakly (e.g., 20%) 
or not at all to the next one or more successive hairs. We 
therefore expanded our criteria for determining mechan-
ical threshold such that it was not based on responses to 
a single hair but rather when an average response of 60% 
was reached over three successive hairs. The logarithmic 
of the bend force value of the second hair in this series 
was established as the mechanical threshold. Series of 
von Frey testing was first performed on the right hind 
paw (ipsilateral) followed by the left hind paw. A cutoff of 
60 g was used because larger filaments lift the paw, pre-
venting accurate assessment of acute pain-induced with-
drawal responses. Testing was performed for three days 
before surgery with the results from the final pre-surgery 
day used as baseline. Surgery was performed and testing 
was then performed on days 1, 3 and 7 post-surgery.
Application of thermal stimuli
Thermal testing was performed using a radiant heat stim-
ulus from a focused incandescent light source as previ-
ously described [22]. After von Frey testing, rats were 
placed unrestrained under plastic enclosures on an ele-
vated glass platform. The enclosures (23 × 13 × 13 cm) 
were large enough for the rats to move around. Rats were 
allowed to habituate for 5–10  min before testing. Care 
was taken to keep the glass surface dry and free of debris 
or excrement. Latency before paw withdrawal was taken 
as the readout of thermal sensitization. The intensity 
of the light beam was adjusted to provide a reflex with-
drawal latency of approximately 6–8  s in naive animals. 
The mid-plantar footpad was tested twice for each hind 
paw. A minimum of 3 min was allowed between testing 
of the same paw to minimize sensitization.
Table 1 Number of animals used for microarray and QPCR 
analyses
Post surgery days 1 3 7
Microarray
 rhBMP/2/ACS N = 6 N = 6 N = 6
 Vehicle/ACS N = 6 N = 6 N = 6
 No sponge N = 6 N = 6
QPCR
 rhBMP/2/ACS N = 5 N = 7 N = 5
 Vehicle/ACS N = 5 N = 6 N = 5
 No sponge N = 5 N = 5
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RNA isolation and quantitative PCR
Animals were sacrificed 1, 3 or 7  days post-surgery, L4 
and L5 DRG and the corresponding dorsal spinal cord 
were removed, rinsed with PBS, quickly blotted and snap 
frozen on dry ice. To isolate RNA, tissue was sonicated 
in Trizol Reagent (Life Technologies), followed by puri-
fication with the RNeasy Mini Kit (Qiagen) according to 
manufacturers instructions. cDNA was synthesized from 
200  ng RNA using Superscript III (Life Technologies) 
and QPCR performed using SYBR Green (Qiagen) in a 
CFX96 real time system (BioRad) with the primers listed 
in Table 2.
Expression of the housekeeping gene GAPDH was 
assessed in duplicate in parallel wells. Expression of 
target RNA was normalized to GAPDH, and relative 
changes in mRNA expression levels between control and 
treated samples were calculated by the delta delta thresh-
old cycle (∆∆Ct) method as previously described [23] 
using BioRad CFX96 Manager software.
Immunohistochemistry
Animals on post-operative days 7–8 were perfused with 
ice-cold PBS followed by 4% paraformaldehyde. Con-
tralateral and ipsilateral DRGs (L4 and L5) were removed, 
post-fixed overnight in 4% paraformaldehyde and then 
transferred to 30% (w/v) sucrose solution for at least 
48  h at 4  °C. For assessment of cell infiltration into the 
spinal nerve, approximately a 2 cm stretch of nerve was 
taken along with the corresponding L4 or L5 DRG. DRG 
samples were then embedded in O.C.T. and sectioned at 
20  µm by cryostat. Sections were blocked with 5% nor-
mal goat serum in PBS and 0.3% Triton X-100 (TX) for 
1  h. The following antisera were used: anti-GFAP, rab-
bit polyclonal (1:1000, DAKO Z0334); anti-ED-1, mouse 
monoclonal (1:500, Millipore MAB1435); and anti-IBA-1, 
rabbit polyclonal (1:1000, Wako, 019-19741). Fluorescent 
labeling with secondary antibodies was performed using 
Alexa Fluor 568 goat anti-mouse and Alexa Fluor 488 
goat anti-rabbit (1:500, Invitrogen, A11031 and A-11034, 
respectively). Images were acquired using an Olympus 
BX61 inverted microscope attached to a Retiga EXi Aqua 
CCD camera using iVision software (BioVision Tech-
nologies). Cell counts of 10× images were performed 
using ImageJ software (National Institutes of Health). 
The section with the greatest number of immunoposi-
tive cells (chosen from a maximum of four per slide with 
inter-section intervals of 400 µm) was used to represent 
cell counts per animal. Cell counts were calculated as the 
number of immunopositive cells per unit area of tissue, 
as the field of view at 10× was rarely but occasionally 
larger than the size of the tissue.
BeadChip genome‑wide RNA expression analysis
Genome-wide RNA expression analysis was performed 
as previously described [24, 25]. Briefly, RNA was isolated 
from DRGs with the RNeasy Mini Kit (Qiagen). Total RNA 
integrity was determined with the RNA Nano 6000 chip 
on the Agilent 2100 Bioanalyzer. Total RNA with a RNA 
Table 2 Primers used for QPCR
Gene Forward Reverse Amplicon Tm (°C)
Sequence Position Sequence Position
ATF-3 TGCCTGCAGAAGGAGTCAGAG 494–514 CTTCCGGCGTCCGCCCGTTCT 650–630 157 56
CD68 AATTCACCTGGACCTGCTCTC 837–857 ACGCAGAAGGCAATGAGCACC 1004–984 168 54
C-FOS CTGTCAACACACAGGACTTTT 262–282 CGCTCTGGTCTGCGATGGGGC 410–390 149 50
CGRP AACCTTAGAAAGCAGCCCAGGCATG 102–126 GTGGGCACAAAGTTGTCCTTCACCA 442–418 246 59
COL18A1 AGGTAAGGATCTGGGCTA 3064–3081 CCTCGTTGTCCGTCCCG 3237–3221 174 50
COX-2 CGAGGACTGGGCCATGGAGTG 746–766 ACCTCTCCACCGATGACCTGA 864–844 119 57
DYN GCCCCAGCAGGAAGGGTGATA 211–231 CAGGGACGAAATCAGGGGGTT 371–359 157 57
GAPDH ACCATCTTCCAGGAGCGAGA 292–311 GGCGGAGATGATGACCCT 438–421 147 56
ID1 GTGAGCAAGGTGGAGATACTG 304–321 GCTGGAACACATGCCGCCTCG 482–462 179 52
IL-1β GACCCCAAAAGATTAAGGATT 136–156 AAAGAAGGTGCTTGGGTCCTC 335–315 200 50
MCP-1 CCAGAAACCAGCCAACTCTC 25–44 CCGACTCATTGGGATCATCT 216–197 192 53
S100A8 GTGCAGAATAAAAATACCGAA 159–179 GCTGTCTTTATGAGCTGCCAC 281–261 123 48
SMAD6 ACTGGATCTGTCCGATTCTAC 873–893 CCGGAGCTCCCAGTACGCCAC 1023–1003 151 50
SMAD7 AGAGTCTCCCCCTCCTCCTTA 755–775 AAGAAGTTGGGAATCTGAAAG 899–879 142 48
SUB P AGAGGAAATCGGTGCCAAC 2128–2107 TGCCCATTAATCCAAAGAACTG 1456–1474 152 52
TNF-α CGGTCCCAACAAGGAGGAGAA 323–343 AGGAGGGCGTTGGCACGCTGG 502–482 180 50
TRPV1 TACTACAAGGGCCAGACAGCA 672–692 GGGGCAGCTCACCAAAGTAGA 834–814 163 55
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integrity number (RIN)  > 8.0 was labeled using a TotalPrep 
RNA Labeling Kit (Ambion) before hybridization on Rat 
Ref-12 Expression BeadChips (Illumina) and imaging by 
the Illumina iScan System at the Lerner Research Institute 
Genomics Core, Cleveland Clinic, Cleveland, OH. Rat Ref-
12 BeadChips allow for probing of ~22,523 well-established 
and provisional annotated transcripts. Raw data generated 
from iScan imaging was outputted using the GenomeStu-
dio software package and Gene Expression module.
BeadArray data analyses
Raw BeadArray data was pre-processed by offset back-
ground subtraction and quantile normalization settings 
using the GenomeStudio data analysis software (Illumina). 
Post-output processing was performed by selecting tran-
script features if the detection p value <0.05 occurred in at 
least 75% of the samples for a experimental group (which 
corresponds with a 95% confidence in accurate detection 
over background beads). Differentially expressed Bead-
Array expression values between vehicle and rhBMP-2 
treatment group samples were determined using the Com-
parativeMarker Selection module within GenePattern 
3.8.0 analysis platform [26]. Differentially expressed Bead-
Array features were filtered for fold changes >1.66 and p 
values <0.1 between groups. Differentially expressed Bea-
dArray features corresponding to transcripts were queried 
for relationships using GO, GATHER, and GSEA [27, 28]. 
Heatmaps of enriched transcript subsets were visualized 
using HeatMapViewer within GenePattern 3.8.0.
DRG explant cultures
Excised DRG from adult naïve rats were briefly rinsed in 
HBSS to remove excess blood from tissue before plac-
ing in a well of 24-well plates containing DRG medium 
(MEM, 5% heat-inactivated horse serum, 10 mM HEPES, 
1  mM Na-pyruvate, GlutaMAX (Life Technologies, NY, 
USA), N-2 (1×, Life Technologies) and 1× antioxidant 
supplement (A1345, Sigma Aldrich, MO, USA). L4 and 
L5 DRGs from the right side of an animal were incubated 
in 1 ml of DRG medium containing rhBMP-2 while the 
DRGs from the left side of the same animal were incu-
bated in medium containing vehicle. After incubating for 
24  h at 37  °C; 5% CO2, DRGs were collected and RNA 
isolated with Trizol. cDNA was synthesized as described 
and expression of different genes analyzed by QPCR. For 
analysis of the effect of different concentrations of BMP-
2, we ran a one way ANOVA for each primer set, with 
Dunnetts correction for comparison to vehicle treated 
explants.
Statistical analysis
For analysis of gene expression in tissue samples removed 
from rats that had surgery performed on one side only we 
performed a repeated measures two way ANOVA match-
ing ipsilateral with contralateral samples for comparison 
of both treatment and side with Sidak’s correction for 
multiple comparisons at each time point. Counting of 
ED1 positive cells in DRG and nerve taken from differen-
tially treated rats was analyzed by two way ANOVA com-
paring distance and treatment. For comparison of the 
number of ED1 positive cells in the DRG or the sciatic 
nerve comparing animals implanted with vehicle/ACS 
or surgery alone, a two tailed students t test was run for 
either the DRG or the sciatic nerve comparing the two 
groups. For assessment of thermal hyperalgesia or tactile 
hypersensitivity data were analyzed using a mixed model 
for repeated measures, with group (BMP2 vs. vehicle) 
and time (pre-op and days 1, 3 and 7) as fixed factors and 
a random subject effect. Separate models were estimated 
for each side (ipsilateral and contralateral). Pairwise com-
parisons between groups at each time point, and between 
days for each group (days 1, 3 and 7 vs. pre-op only) were 
examined only when the corresponding main effect or 
interaction term was statistically significant (p < 0.05). In 
all examinations, a p value of <0.05 was considered statis-
tically significant.
Results
The device which the FDA approved to apply rhBMP-2 
to promote lumbar spine fusion (Infuse®, Medtronic), 
consists of a small metallic cage containing rhBMP-2 in 
carrier type I bovine absorbable collagen sponge to be 
inserted between two vertebrae through an anterior sur-
gical approach [2]. However, the vast majority of off-label 
surgical applications using rhBMP-2 for spinal fusion, 
either utilize a different surgical approach to the interver-
tebral disc (posterior approach), or directly implant the 
rhBMP-2 absorbed in the sponge within the posterolat-
eral spinal space outside the intervertebral disc. Absorba-
ble collagen sponges retain rhBMP-2, providing a half-life 
of rhBMP-2 in  vivo of 2  days, with <5% remaining by 
14 days [29]. We therefore employed a rat model for the 
application of rhBMP-2, by soaking absorbable collagen 
sponges (ACS) with either rhBMP-2 or vehicle and plac-
ing the ACS on the transverse processes across vertebrae 
to promote posterolateral arthrodesis. ACS soaked with 
either rhBMP-2 (80  µg/animal) or vehicle (control) was 
implanted (Fig. 1a). We picked this dose as it is a human 
equivalent dose (HED) of 3 mg for a 70 kg patient which 
is in the middle of the range of the dose of rhBMP-2 that 
a patient would receive [30, 31].
To determine whether implantation of rhBMP-2/ACS 
triggers changes in gene expression in the DRG, we meas-
ured the expression of a subset of known genes involved 
in inflammation, nerve injury, and BMP-2 signaling. 
rhBMP-2/ACS implantation resulted in a significant 
















































































































































Fig. 1 Application of rhBMP-2 in rat model of posterior lateral arthrodesis triggers changes in the PNS and CNS. a Illustration depicting placement 
of rhBMP-2/ACS next to the spine. Of the PNS structures, only the dorsal rami as well as nerves innervating the facet joint (not shown) are likely to 
make direct contact with rhBMP-2/ACS. b QPCR analysis of RNA isolated from ipsilateral and contralateral DRGs of rats 24 h after implantation of 
either rhBMP-2/ACS or vehicle/ACS. DRG samples were assessed using markers of inflammation (Cox-2 and IL-1β), nerve injury (ATF-3), nociceptive 
activity (MCP-1) and BMP-2 signaling (Smad-7 and ID-1) (mean ± SEM, n = 5, *p < 0.05, **p < 0.01). c QPCR analysis of RNA isolated from ipsilateral 
and contralateral dorsal horn spinal cord from the same animals as in 1B, 24 h after implantation of either rhBMP-2/ACS or vehicle/ACS. Increased 
expression of c-fos mRNA, but not dynorphin mRNA was detected in ipsilateral DSC of rhBMP-2/ACS implanted animals (mean ± SEM, n = 5*, 
p < 0.05, **p < 0.01). d QPCR analysis of RNA isolated from DRG explant cultures where L4 and L5 DRG from one side of a rat were combined and 
treated overnight in rhBMP-2 medium while L4/L5 DRG from the other side of the same animal were bathed in control medium (mean ± SEM, 
n = 4, *p < 0.05)
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increase in the expression of the inflammatory marker, 
Cox-2, in the ipsilateral DRG compared to expression in 
the DRG of rats implanted with vehicle/ACS at 1 day post 
surgery (dps) (Fig.  1b). rhBMP-2 did not induce IL-1β, 
ATF-3 or MCP-1 mRNA indicating that rhBMP-2 did not 
globally induce inflammatory genes or those involved in 
nerve injury (Fig. 1b) [32–34]. However, in both groups, 
there was a significant induction of ATF-3 mRNA ipsilat-
eral to surgery compared to the contralateral side. There 
was also no change in mRNA encoding the BMP target 
genes, Smad7 or ID1 mRNA.
We also examined expression of mRNA encoding the 
immediate early gene c-fos and the neuromodulatory 
peptide dynorphin in the dorsal spinal cord (DSC), as 
the DSC receives afferent input from the DRG. At 24  h 
c-fos mRNA, but not dynorphin, was significantly higher 
in the ipsilateral DSC of rhBMP-2 treated animals com-
pared to expression in the ipsilateral DSC of vehicle/ACS 
animals (Fig.  1c). Thus, our data suggest that implanta-
tion of rhBMP-2 onto the spinal column causes changes 
in the DRG and these changes are transmitted to the dor-
sal spinal cord.
As we did not find any change in the expression of the 
BMP responsive genes, Smad7, Id1 or Smad6 (data not 
shown) in rats treated with rhBMP-2 (Fig. 1b), we wanted 
to determine whether cells in the DRG respond to BMP-
2. We therefore treated DRG explant cultures for 24  h 
with different doses of BMP-2. In DRG explant cultures, 
rhBMP-2 induced expression of known target genes Id1 
and Smad7, but did not change expression of the pro-
inflammatory genes, Cox2, IL-1β or TNF-α, nor the noci-
ceptive peptides substance P or CGRP (Fig. 1d). mRNA 
levels coding ATF-3, MCP-1 and the capsaicin recep-
tor TRPV1 were also unaffected by rhBMP-2 treatment. 
Therefore, rhBMP-2 causes different changes in gene 
expression in DRG in explant culture than in innervated 
DRG in vivo.
To determine whether rhBMP-2/ACS induced changes 
in the inflammatory profile of the DRG involved the 
recruitment of immune cells, we examined DRGs for the 
presence of macrophages and neutrophils. rhBMP-2/
ACS did not induce mRNA expression of S100a8, a neu-
trophil marker [35], or CD68, a macrophage marker, 
relative to expression in vehicle/ACS implanted animals 
at any time point (Fig. 2a, b). We did, however, observe 
higher CD68 transcript levels in the ipsilateral hemi-
sphere of both rhBMP-2 (p  <  0.05) and vehicle groups 
compared to their respective contralateral controls sug-
gesting increased presence of macrophages with sur-
gery (Fig. 2b). Immunohistochemical analysis confirmed 
detection of ED1+ macrophages in the DRG and spinal 
nerve of both rhBMP-2 and vehicle groups (Fig.  2c). 
ED1+ macrophages were rarely detected near nerve 
fibers in naive animals (data not shown). Equal numbers 
of ED1+ macrophages were found in the spinal nerve of 
rhBMP-2 and vehicle treated animals on days 7–8 with a 
gradient of macrophages observed—higher closer to the 
DRG and decreasing more distal to the DRG (Fig.  2d). 
ED1+ cells throughout the nerve comprised a subpopu-
lation of IBA1+ macrophages, and were generally larger 
than the IBA1+/ED1− population (Fig.  2e, f ). Together, 
these data suggest that the surgery and/or implantation 
of the ACS contribute to the increased macrophage pres-
ence in the spinal nerve.
To assess changes in DRG that may reflect responses 
by resident as well as infiltrating cells following arthro-
desis surgery, we performed genome-wide RNA expres-
sion profiling on samples obtained from rats implanted 
with either rhBMP-2/ACS or vehicle/ACS rats at post-
operative day 1, 3 and 7. Analysis of expression levels 
between groups at each time point identified 107, 216 
and 245 candidate transcripts at the 1, 3 and 7 day points 
respectively, with significant expression level differ-
ences between rhBMP-2 and vehicle-control treatment 
subjects (data not shown). A significant relationship (p 
value <0.0001 was observed between 37 of the individu-
ally annotated transcripts for functions associated with 
immune response (GO:0006955), response to wounding 
(GO:0009611) and inflammatory response (GO:0006954) 
using gene ontology and gene set enrichment analy-
sis (Fig.  3). The most significant stratification between 
DRG samples from vehicle/ACS and rhBMP-2/ACS sub-
jects was observed at 3 dpi (Fig. 3, center green outlined 
panel).
A recent meta-analysis study reported that nearly 
8 percent of patients that have undergone rhBMP-2 
assisted posterolateral arthrodesis experience post-oper-
ative clinical pain [5]. To test whether the cellular and 
molecular changes mediated by rhBMP-2/ACS in our 
rodent model of posterolateral arthrodesis alters pain 
sensitivity, we assessed rats for development of thermal 
hyperalgesia and mechanical hypersensitivity. Thermal 
nociceptive responses of vehicle and rhBMP-2 animals 
were assessed by measuring the latency of ipsilateral and 
contralateral hind paw withdrawal from a noxious radi-
ant heat stimulus at different time points after implanta-
tion of either rhBMP-2/ACS or vehicle/ACS (Fig. 4a, b). 
Baseline latency durations were acquired for each ani-
mal before surgery to provide the comparison “pre-op” 
value. It should be noted that baseline latency durations 
for the rhBMP-2/ACS animals were 1.63 (ipsilateral) and 
1.38  s (contralateral) longer than vehicle/ACS animals. 
Statistical analysis indicated that on the ipsilateral side 
there were significant main effects of both group and 
time, but the difference between groups did not vary over 
time. Differences between the treatment groups were 
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significant at 7  dps (p =  0.019) and approached signifi-
cance at 3 dps (p = 0.080). Withdrawal latency changes 
relative to values in the same animals before the surgery 
(pre-op) were significant only in those implanted with 
rhBMP2/ACS at 1 dps (p = 0.018). On the contralateral 
side there were also significant main effects of both group 
and time. Differences between groups were significant at 
3  dps (p =  0.006) and approached significance at 1  dps 
(p  =  0.077). Thus, rats implanted with rhBMP-2/ACS 
were more sensitive to thermal stimuli at different time 






































































Fig. 2 Increased numbers of macrophages in the DRG and spinal nerve of rats implanted with either rhBMP-2/ACS or vehicle/ACS. a, b QPCR analy-
sis of RNA isolated from ipsilateral and contralateral DRGs 1, 3 or 7 days after implantation of rhBMP-2/ACS or vehicle/ACS. There was no induction 
of S100a8 mRNA (a neutrophil marker) at any time point, but at 7 dps, CD68 mRNA was induced ipsilateral to implantation of either rhBMP-2/ACS or 
vehicle/ACS (mean ± SEM, n = 5, *p < 0.05). c Representative immunohistochemistry image showing ED1+ cells 8 dps in the DRG and spinal nerve 
of rhBMP-2 and vehicle ACS implanted rats. d Number of ED1+ macrophages/field in rhBMP-2 or vehicle (control) rats in the DRG (green arrowhead), 
spinal nerve (the pink arrowhead most proximal to DRG) and ventral rami (remaining arrowheads depicting different locations) (mean ± SEM, n = 6 
animals/group). e, f Representative double staining of spinal nerve from 7 dps rhBMP-2/ACS animals with anti-ED1 and anti-IBA1 antibodies. Images 
show that all ED1+ cells are IBA1+ (yellow arrows). There were, however, IBA1+ cells that were ED1− (white arrow) and these cells were generally 
smaller than the ED1+ population. Higher magnification (× 40) reveals multiple vacuoles in ED1+ population of macrophages (F)
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Stimulation of hind paws with von Frey hairs was used 
to assess for mechanical hypersensitivity (Fig.  4c, d). 
Statistical analysis indicated that on the ipsilateral side 
there were no significant differences between BMP2 and 
vehicle groups at any one time point, but there was a 
significant main effect of time, indicating that log(force) 
changed over time for the BMP2 and vehicle groups com-
bined. Indeed the rats became hyposensitive at 1  dps, 
followed by a hypersensitivity to this mechanical stimu-
lation at 3  dps. Follow-up analysis indicated that the 
BMP-2 group showed a significant increase in log(force) 
on 1  dps compared to pre-op (p  =  0.029), and a trend 
towards a significant decrease (hypersensitivity) at 3 dps 
(p  =  0.090). On the contralateral side there was also a 
significant main effect of time, but none of the compari-
sons with pre-op reached statistical significance (1 dps vs. 
pre-op approached significance, p = 0.055), in line with 
a generalized hyposensitivity at 1 dps, and there were no 
statistical differences between treatment groups on the 
contralateral side. Thus, implantation with rhBMP-2/
ACS led to a mild, non-significant hypersensitivity to 
mechanical stimuli at 3 dps.
The appearance of increased ED1+ macrophages in the 
DRG and spinal nerve of animals after implantation of 
ACS with either rhBMP-2 or vehicle suggested that the 
carrier ACS may have a role in recruitment of these mac-
rophages and hence the development of inflammation. 
We therefore compared cellular and molecular changes 
in surgically incised animals after vehicle/ACS implan-
tation with rats that underwent surgery without ACS 
implantation. CD68 mRNA expression trended higher in 
the ipsilateral DRG of animals implanted with the ACS 
than those with surgery alone on day 7 (Fig. 5b). Immu-
nohistochemical analysis indicated that there were sig-
nificantly greater ED-1+ macrophages in the ipsilateral 
DRG and spinal nerve of 7 days ACS implanted rats com-
pared to the surgery only controls (Fig. 5c, d) suggesting 
that the presence of ACS rather than surgery alone was 
responsible for the increased expression of ED-1. In con-
trast, the nerve injury marker ATF-3 was similarly ele-
vated in the ipsilateral DRGs of both groups compared to 
contralateral DRG at 24 h (Fig. 5a).
Genome-wide RNA expression analysis indicated that 
ACS implantation results in significant transcriptome 
alterations in the DRG compared to surgery alone. Clus-
tering of genome-wide RNA expression signatures from 
DRG samples at 1 and 3 dps shows a complete stratifica-
tion of subjects by time as well as a partial stratification 
of subjects by ACS presence (Fig. 5e). ACS presence was 
found to be associated with differential expression levels 
between groups for 80 candidate transcripts at 1 dps and 
298 candidate transcripts at 3 dps (data not shown). The 
complete set of differentially expressed transcripts associ-
ated with ACS presence were observed to be significantly 
(p value 0.0002) enriched for a subset of 19 transcripts in 
functions in tissue morphogenesis (GO:0009653) associ-
ated with muscle development (GO: 0007517) (Fig.  5e). 
At 3  dps, there was strong repression of genes encod-
ing signaling molecules such as angiopoietin1, sema-
phorin6B, IGF-2 and frizzled related protein and strong 
induction of muscle related genes such as troponin T 
type 3, troponin C type 2 and myosin heavy chain 7 
(Fig.  5e). Interestingly, the differentially expressed tran-
scripts associated with ACS presence was not observed 
to be significantly enriched for immune or inflammatory 
response as compared with tissue transcriptome profiling 
from DRGs isolated from rhBMP-2/ACS rats. These data 
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Fig. 3 Microarray analysis indicates that rhBMP-2 induces many 
genes involved in neuroinflammation in the DRG. Heat map showing 
genes whose expression was altered at 1, 3 and 7 dps in the ipsilateral 
L4/L5 DRGs of rhBMP-2/ACS or vehicle/ACS implanted rats. Blue color 
intensity indicates decreasing transcript expression as compared 
to the mean value across all samples. Red color intensity indicates 
increasing transcript expression as compared to the mean value 
across all samples. The green outlined panel indicates high significant 
differences at 3 dpi. Each column represents data from RNA extracted 
from one rat
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show that implantation of the ACS alone causes signifi-
cant changes in gene expression in the DRG, that are not 
attributable to the effects of surgery.
Discussion
rhBMP-2 use in clinical arthrodesis is complicated with 
adverse side effects including pain and inflammation [5, 
30]. In the present study, using a rat model of rhBMP-2 
posterolateral arthrodesis, we show that rhBMP-2 
induces a transient increase in thermal and mechanical 
sensitivity. This effect was accompanied by robust neu-
roinflammatory changes in and around the DRG, with 
some changes also transmitted to the dorsal spinal cord. 
We also observed that implantation of the absorbable 
collagen sponge alone is sufficient to cause macrophage 
recruitment to the DRG and spinal nerve even in the 
absence of rhBMP-2. Our studies suggest the inflamma-
tory changes and altered pain sensitivity observed during 
rhBMP-2 arthrodesis may be mediated by a combination 
of effects caused by the rhBMP-2 and the ACS.
We determined that posterior lumbar fusion (PLF) 
surgery in rats was suitable for modeling some of the 
effects of rhBMP-2 on pain and inflammation. How-
ever, our procedure was different from clinical anterior 
or posterior lumbar interbody fusion surgeries (ALIF 
or PLIF) where the rhBMP-2/ACS is placed within a 
small metallic cage and then inserted into the interver-
tebral disc. In our model the ACS is placed directly on 
the transverse processes within the posterolateral spi-
nal space outside the intervertebral disc rather than 
being placed within the restricted disc space, as the 
rodent intervertebral disc space is too small. Thus our 
model relates more to the off label use of rhBMP-2/
ACS and does not investigate the intervertebral usage. 
Due to placement of the ACS the L4/L5 dorsal rami 
are unavoidably irritated and often cut during incision 
and muscle clearance. Damage to the dorsal rami may 
explain the ipsilateral ganglionic increase in ATF-3 with 
surgery, as ATF-3 induction is widely considered an 




































































Fig. 4 Behavioral responses of rhBMP-2/ACS or vehicle/ACS implanted rats to acute painful stimuli. Transient effects of rhBMP-2 in spinal arthrode-
sis model on withdrawal responses (presented as withdrawal latency) to noxious thermal stimulation (a ipsilateral and b contralateral; mean ± SEM, 
n = 11). Effects of rhBMP-2/ACS implantation on mechanical pain sensitivity as assessed with von Frey hair stimulation (c ipsilateral and d contralat-
eral). Line graph presented as mean ± SEM of the log of the threshold von Frey hair bend force (mean ± SEM, n = 11). Statistical significance in a–d 
are represented as *p < 0.05, where comparisons are against pre-operative baseline for ipsilateral or contralateral or #p < 0.05 comparing different 
treatment groups at the same time point
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We did not detect induction of known BMP-2 respon-
sive genes—ID1 and Smad6 in the DRGs removed from 
rats implanted with rhBMP-2/ACS. Instead, rhBMP-2/
ACS implantation resulted in an increase in ganglionic 
expression of inflammatory-related genes such as Cox-2. 
However, direct rhBMP-2 treatment of explanted DRGs 
did induce ID1 and Smad7 mRNA, but not Cox-2 or 
other inflammatory genes. There could be several dif-
ferent explanations for this differential regulation of 
gene expression between direct rhBMP-2 treatment of 
DRG explant cultures, and rhBMP-2/ACS implantation-
induced changes in DRG neurons in vivo. First, the effect 
of rhBMP-2 on DRGs in  vivo could be indirect, possi-
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Fig. 5 Implantation of ACS next to spine is sufficient for triggering numerous molecular and cellular changes in DRG and spinal nerve. a, b QPCR 
analysis of RNA isolated from ipsilateral and contralateral DRGs of rats 1 or 7 days (ATF-3 and CD68, respectively) after either implantation of vehicle/
ACS (sponge) or the same surgical incisions but without ACS implants (no sponge) (mean ± SEM, n = 4 *p < 0.05). c Representative image of immu-
nohistochemistry of ED1+ cells in the spinal nerve of rats with or without ACS implanted. d Cell counts of ED1+ macrophages in the DRG and spinal 
nerve of the same animals (mean ± SEM, n = 5 animals/group, *p < 0.05). e Heat map showing differential expression of genes in DRG at 1 and 
3 dps with implantation of vehicle/ACS (sponge) in comparison to surgery alone (no sponge), as determined by bead chip analysis. Blue color inten-
sity indicates decreasing transcript expression as compared to the mean value across all samples. Red color intensity indicates increasing transcript 
expression as compared to the mean value across all samples. Each column represents data from RNA extracted from one rat
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presence of the implanted ACS. As the peak inflamma-
tory response after rhBMP-2/ACS implantation at 3 dps 
was prior to the observed significant macrophage infil-
tration at 7 dps, an indirect effect through macrophages 
is unlikely. An indirect effect would also imply that the 
rhBMP-2 in the ACS was not accessible in our model 
to DRG neurons. Indeed, in support of a lack of direct 
BMP-2 signaling to DRG neurons we were unable to find 
any difference in pSmad1/5/8 staining between DRGs 
taken from rhBMP-2/ACS or vehicle/ACS rats (data not 
shown). Thus, the mechanism through which BMP-2 dif-
ferentially alters DRG gene expression in vivo and in vitro 
requires further evaluation.
We detected mild transient changes in mechanical 
and thermal sensitivities at 1 and 3  dps (Fig.  4). This 
time course correlates with the increased proinflamma-
tory gene expression at 1 and 3 dps (Fig. 3). It is widely 
accepted that peripheral neuroinflammation leads to 
sensitization of nociceptors thereby altering pain sensi-
tivity [37]. In the DRG, inflammatory mediators includ-
ing pro-inflammatory cytokines released from resident 
cells as wells as blood-derived immune cells can act 
locally to sensitize nociceptors. BMP-2 itself, although 
most prominently known for pro-morphogenic roles, 
can exert numerous pro-inflammatory effects [17, 20, 
21, 38]. Administration of rhBMP-2 increases levels of 
circulating pro-inflammatory and osteoclastic cytokines 
in a rodent model of PLF [39]. Clinically, rhBMP-2 has 
been reported to cause life threatening cervical swell-
ing when used for anterior cervical fusions [7] which 
resulted in the FDA warning against its use in this set-
ting [10]. Also, we have previously shown that rhBMP-2 
triggers potent neuroinflammatory changes after spi-
nal cord injury [18, 40]. Therefore a generalized rapid 
increased inflammatory environment surrounding the 
DRG neurons after rhBMP-2/ACS implantation could 
explain the transient increase in thermal and mechani-
cal sensitivity we found. Our data are in contrast to 
those of Zanella et  al. [41] who find no direct effect 
of either rhBMP-2/ACS or ACS alone on the thermal 
hypersensitivity that results after direct application 
to the sciatic nerve in the chronic constriction injury 
(CCI) neuropathic pain model. However, the CCI model 
causes significant inflammation by itself [42], so it is not 
clear whether additional inflammatory stimuli would 
further increase the large nociceptive changes seen in 
this model. In our model, the increased nociception 
was very transient, which is largely different from the 
clinical scenario [30, 43]. As we showed that rhBMP-2 
driven bone formation did not occur during the first 
7  days after surgery, the thermal and mechanical pain 
we detected within the first week can not be attributed 
to ectopic-bone mediated nerve root compression.
The infiltration of macrophages in the DRG and spi-
nal nerve is an indication of a robust neuroinflammatory 
response evoked in the present arthrodesis model. Our 
findings indicate that the ACS was a significant cause 
of infiltrating macrophages as these macrophages were 
detected in vehicle/ACS animals, but not in those that 
underwent surgery without ACS implantation (Fig.  5). 
Our data are in agreement with those in a recent publica-
tion that shows increased inflammatory volume following 
intramuscular implantation of ACS alone, that was inter-
mediate between the edema following surgery alone, and 
that of rhBMP-2/ACS implantation [21]. Macrophages 
are well known to participate in resorption of ACS [44]. 
Indeed, these macrophages express ED1, a marker for 
phagocytizing macrophages and many contained promi-
nent vacuoles (Fig.  5) suggestive of engulfing activities. 
As we did not detect large numbers of these macrophages 
until 7  dps, after the pain responses we monitored had 
returned to baseline, it is possible that these macrophages 
have more of a reparative role in resorption of the ACS, 
rather than release of pro-inflammatory cytokines that 
would sensitize the nociceptors. ACS implantation alone 
resulted in numerous other molecular changes includ-
ing alterations in expression of several genes involved 
in tissue morphogenesis. Thus, vehicle/ACS implanta-
tion alone was not sufficient to trigger the inflammatory 
milieu. This pro-inflammatory environment required the 
rhBMP-2 and the ACS.
Conclusions
This manuscript shows that rhBMP-2/ACS implanted 
onto the spine results in neuroinflammatory changes in 
the adjacent DRG and spinal nerve. Implantation of the 
ACS and exposure to rhBMP-2 resulted in distinct influ-
ences on the tissue microenvironment. An interaction of 
these influences resulted in neuroinflammation and an 
associated increase in pain sensitivity. These experiments 
may help explain the molecular basis for the develop-
ment of radiculitis after lumbar arthrodesis and provide a 
rationale for the development of alternative delivery sys-
tems that could ameliorate neuroinflammatory sequelae 
of rhBMP-2 induced arthrodesis.
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